Cover Image
市場調查報告書

白三烯A4水解酶:開發中產品分析

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 369081
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
白三烯A4水解酶:開發中產品分析 Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H1 2017
出版日期: 2017年06月20日 內容資訊: 英文 40 Pages
簡介

本報告提供以白三烯A4水解酶為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關開發中之治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

白三烯A4水解酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Celtaxsys, Inc.
  • Johnson & Johnson
  • 日本化藥

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0849TDB

Summary

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Leukotriene A4 hydrolase (LTA4H) is an enzyme which converts leukotriene A4 to leukotriene B4 and acts as an aminopeptidase. LTB4 is a potent lipid chemoattractant involved in inflammation, immune responses, host defense against infection and PAF-induced shock.

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Cardiovascular, Respiratory, Dermatology and Hematological Disorders which include indications Pulmonary Arterial Hypertension, Acne Vulgaris, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Emphysema and Lymphedema.

The latest report Leukotriene A 4 Hydrolase - Pipeline Review, H1 2017, outlays comprehensive information on the Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6)
  • The report reviews Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Overview
    • Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Companies Involved in Therapeutics Development
    • Celtaxsys Inc
    • Johnson & Johnson
    • Nippon Kayaku Co Ltd
  • Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Drug Profiles
    • acebilustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTX-3397 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDO-66 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-26993135 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Leukotriene B4 for Chronic Obstructive Pulmonary Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ubenimex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Dormant Products
  • Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Product Development Milestones
    • Featured News & Press Releases
      • May 17, 2017: Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
      • May 17, 2017: Celtaxsys Announces Full Enrollment of Its Landmark EMPIRE-CF Phase 2b Clinical Trial Assessing the Potential of Novel Anti-inflammatory Investigational Therapy, Oral Acebilustat, to Preserve Lung Function in CF Patients
      • May 15, 2017: Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
      • May 04, 2017: Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City
      • Jan 03, 2017: Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
      • Nov 03, 2016: Celtaxsys Announces Publication of Clinical Trial Results Demonstrating Novel Anti-inflammatory Medicine, Oral Acebilustat, Reduced Lung Inflammation Without Increased Risk of Immunosuppression, in CF Patients
      • Oct 28, 2016: Celtaxsys Announces Publication of Results Demonstrating Safety, Tolerability and PK/PD Profile of Novel Anti-inflammatory Medicine, Oral Acebilustat, in Phase 1 Clinical Trials including CF Patients
      • Jul 25, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema
      • Jul 18, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
      • May 03, 2016: Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
      • Mar 28, 2016: Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency
      • Dec 15, 2015: Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension
      • Dec 01, 2015: Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference
      • Nov 30, 2015: Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary
      • Oct 08, 2015: Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Celtaxsys Inc, H1 2017
  • Pipeline by Johnson & Johnson, H1 2017
  • Pipeline by Nippon Kayaku Co Ltd, H1 2017
  • Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
Back to Top